Barclays PLC V Tv Therapeutics Inc. Transaction History

Barclays PLC

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$0.95 - $1.69 $1,450 - $2,580	-1,527 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$1.53 - $2.22 $2,597 - $3,769	-1,698 Reduced 52.65%	1,527 $2,000
Q2 2021 Aug 13, 2021	SELL	$2.27 - $3.44 $15,163 - $22,979	-6,680 Reduced 67.44%	3,225 $7,000
Q1 2021 May 13, 2021	BUY	$1.97 - $2.89 $12,497 - $18,334	6,344 Added 178.15%	9,905 $28,000
Q4 2020 Feb 11, 2021	SELL	$1.49 - $3.1 $1,601 - $3,332	-1,075 Reduced 23.19%	3,561 $7,000
Q3 2020 Nov 12, 2020	SELL	$1.7 - $2.98 $1,008 - $1,767	-593 Reduced 11.34%	4,636 $9,000
Q2 2020 Aug 12, 2020	BUY	$1.74 - $3.19 $6,253 - $11,464	3,594 Added 219.82%	5,229 $12,000
Q1 2020 May 13, 2020	SELL	$1.63 - $3.75 $205,256 - $472,215	-125,924 Reduced 98.72%	1,635 $3,000
Q4 2019 Feb 10, 2020	BUY	$1.37 - $1.97 $174,755 - $251,291	127,559 New	127,559 $217,000
Q3 2019 Nov 14, 2019	SELL	$1.26 - $1.77 $5,847 - $8,214	-4,641 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$1.29 - $1.83 $30,133 - $42,746	-23,359 Reduced 83.43%	4,641 $7,000
Q4 2018 Feb 14, 2019	BUY	$0.78 - $3.74 $17,160 - $82,280	22,000 Added 366.67%	28,000 $74,000
Q3 2018 Nov 14, 2018	SELL	$0.7 - $1.58 $6,256 - $14,122	-8,938 Reduced 59.83%	6,000 $5,000
Q2 2018 Aug 14, 2018	BUY	$0.71 - $4.04 $9,127 - $51,934	12,855 Added 617.14%	14,938 $23,000
Q1 2018 May 15, 2018	BUY	$3.91 - $7.83 $78 - $156	20 Added 0.97%	2,083 $8,000
Q4 2017 Feb 14, 2018	BUY	$3.9 - $7.77 $6,165 - $12,284	1,581 Added 328.01%	2,063 $13,000
Q3 2017 Nov 14, 2017	BUY	$3.83 - $6.07 $1,846 - $2,925	482	482 $3,000

243K

Ticker VTVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,483,600
Market Cap $1.1B
Description
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetran...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.